Tanespimycin - Kosan Biosciences
Alternative Names: 17-AAG; 17-allylamino-17-demethoxy-geldanamycin; KOS-953Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator National Institutes of Health (USA)
- Developer Kosan Biosciences
- Class Antineoplastics; Benzoquinones; Cytostatic antibiotics; Macrocyclic lactams; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HER2 positive breast cancer; Malignant melanoma; Multiple myeloma
Most Recent Events
- 05 Dec 2009 Efficacy, adverse events and pharmacodynamics data from a phase II/III trial in Multiple myeloma presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
- 04 Dec 2009 No development reported - Phase-II for Malignant melanoma in Australia (IV)
- 04 Dec 2009 No development reported - Phase-II for Malignant melanoma in USA (IV)